Blog | BioInformant

Aegle Therapeutics Prepares Phase 1/2a Trial of BM-MSC Derived Extracellular Vesicles

July 20, 2018 By Cade Hildreth, Founder & President Leave a Comment

Aegle Therapeutics Corporation is the first extracellular vesicle (EV) company to be cleared by the FDA to enter clinical trials in humans. Headquartered in Miami, FL, the company is using allogeneic bone marrow mesenchymal stem cell (BM-MSC) derived extracellular vesicles to treat severe dermatological disorders, with a focus on burn treatments.

In May 2018, Aegle announced that the FDA cleared its first Investigational New Drug (IND) application to initiate a clinical trial in severe second degree burn patients. The company plans to launch a Phase 1/2a clinical trial of its lead product AGLE-102 in late 2018.

The open label dose escalation study will enroll patients at several sites in the U.S., evaluating the safety of extracellular vesicle therapy in burn patients. [Read more…]

Two-Year-Old Emirati Boy Saves Older Brother with Stem Cells Stored with CryoSave Arabia

July 18, 2018 By Cade Hildreth, Founder & President 1 Comment

Cryo-Save Arabia - Sickle-Cell — Hamad Alyaarbi

Dubai, UAE, July 2018 – Hamad Alyaarbi an eight-year-old Emirati boy who suffers from the debilitating condition Sickle Cell Anemia, has had his disease cured thanks to the use of stem cells from his younger brother, Abdullah, that were stored by CryoSave Arabia. At the beginning of 2017 Hamad’s parents had made the decision to use the cord blood stem cells from his younger brother, Abdullah, for a transplant to try and save his life. The transplant took place on 23rd June 2017, and almost a year later, Hamad is now completely cured and living a happy, healthy life, disease-free. [Read more…]

Steminent Announces FDA Approval of IND for Phase II Clinical Trial of Stemchymal® SCA in the Treatment of Spinocerebellar Ataxia

July 18, 2018 By Cade Hildreth, Founder & President Leave a Comment

San Diego, CA, USA, July 18th, 2018 – Steminent Biotherapeutics Inc. (“Steminent” or “Company”) a private, clinical-stage cell-therapy company with offices in Taiwan, San Diego and Shanghai, is pleased to announce that the United States Food and Drug Administration (“FDA”) has raised no objections to the Company’s Investigational New Drug (“IND”) application. This allows the Company to initiate its Phase II clinical trial for polyglutamine spinocerebellar ataxia (“PolyQ SCA”) to enroll patients at clinical sites in the United States. This is a key milestone for the Company’s international Stemchymal® SCA Phase II clinical trials program. [Read more…]

How Much Does Cord Blood Banking Cost?

July 18, 2018 By CadeHildreth Leave a Comment

Cord blood banking is an option available to most any parent after the birth of their child. There are proven benefits to the stem cells you can easily collect and store through the birthing process, although this is generally not common knowledge. While the cost of storing cord blood can often be more than parents want to pay, it might be a good idea to know what your options are before you decide.

This article will provide you with answers to some of the key questions about cord blood banking and stem cells in general. Read ahead to better understand why you might want to consider cord blood banking. [Read more…]

American Association of Stem Cell Physicians to Host Miami Summit | August 10-12 (24 CME)

July 17, 2018 By Cade Hildreth, Founder & President 1 Comment

The American Association of Stem Cell Physicians (AAOSCP) is an organization created to advance research and the development of therapeutics in regenerative medicine, including diagnosis, treatment, and prevention of disease related to or occurring within the human body.

The AAOSCP aims to serve as an educational resource for physicians, scientists, and the public in diseases that can be caused by physiological dysfunction that are ameliorable to medical treatment.

The organization’s annual summit will be held this year at the Mandarin Oriental Miami, Florida, from Friday, August 10th to Sunday, August 12th, 2018.

Reasons to Attend AAOSCP’s 2018 Summit

The conference will feature three days of educational and social events with leading physicians and pioneers in the fields of stem cells and regenerative medicine.

It will be an opportunity to meet, workshop, and network with prominent doctors and scientists from around the world.

It will also feature two hour interactive workshops with small participant-to-instructor ratios and a customized curriculum focusing on developing hands-on skills. Each technique will be taught by experts in the field, using didactic sessions with dynamic multimedia presentations, live demonstrations and scanning on live model, as well as phantoms.

Physicians will have the opportunity to earn up to 24 CME credits. [Read more…]